Adaptive Design in Clinical Trials: When and How to Apply

Back to Agenda

Session 4: Regulatory Guidance from the FDA

Chief Scientific Officer of Artificial Intelligence and Digital Science and SVP,

Pfizer Inc, United States

General concerns associated with using adaptive designs

Well understood and less-well understood adaptive designs

Statistical considerations for less-well understood adaptive designs

Considerations for Adaptive Design Protocol

Safety Considerations in Adaptive Trials

Have an account?